Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
AQP9 (aquaporin 9) was first discovered in adipose tissue, and the AQP9 gene was successfully cloned. There are also AQP9 in tissues such as testis, spleen, white blood cells, liver, and brain. AQP9 belongs to the sub-group of hydroglycerin channels and is transparent to many small molecules such as water, urea, guanidine and pyrimidine. AQP9 is abundant in brain tissue and is distributed in the central nervous system on the cell membranes of astrocytes, vascular endothelial cells, and special types of catecholamine-like neurons. Compared with other AQPs, AQP9 is unique in structure, distribution, and function.
Figure 1. Signaling pathways reported thus far to be involved in regulating the hepatic expression of AQP9. (Lebeck. 2014).
The human AQP9 gene is located on the chromosome 15q21.3 and contains 6 exons. The AQP9 protein is a glycoprotein polypeptide chain with a relative molecular mass of 300 kDa and the same basic structure as other AQPs. Each of the aqueous pores of AQP9 has independent water permeabilization activity, and the basic structure constituting these water pores is an α-helix of 6 times across the cell membrane. The four monomers consisting of these α helices form homotetramers which form a high-order structure of AQP9 with a central void. The homotetramer is only distributed on the cell membrane, and this distribution characteristic is a prerequisite for maintaining the stability and normal function of AQP9.
In the distribution and localization study of AQP9, Wang et al. found that AQP9 is mainly distributed in astrocytes of the periventricular organs, choroid plexus, subgingival organs and periventricular parenchyma. Because the main physiological functions of the organs around the ventricle are involved in cerebrospinal fluid reflux and regulate the activity of neuroactive substances, suggesting that AQP9 may be involved in regulating cerebrospinal fluid circulation, maintaining central nervous system stability, and maintaining brain energy metabolism balance.
AQP9 Regulation in Brain Tissue
Regulation of AQP9 by Hormone
AQP9 is permeable to brain energetic substances such as glycerol and monocarboxylic acid and AQP9 is expressed in catecholamine-like neurons. As a result, these neurons are associated with energy metabolism balance and diabetic neuroendocrine function. In addition, it is known that intracerebral injection of insulin is also associated with energy metabolism balance. The researchers studied the effect of insulin on the expression of AQP9 in brain tissue through a rat model of in vivo diabetes and in vitro cell culture, and used immunohistochemistry to determine the expression pattern of AQP9 cells affected by insulin. It was found that in the brain tissue of diabetic rats, AQP9 expression was only increased in catecholamine-like neurons, but there was no change in AQP9 content in cerebral cortex and cerebellum.
Diabetic rat models and in vitro brain tissue sections showed that the expression level of brain AQP9 can be regulated by different concentrations of insulin. It is speculated that central nervous system AQP9 is related to brain energy metabolism. In addition, a study on the regulation mechanism of AQP9 by in vitro astrocyte culture revealed that protein kinase A (PKA) and protein kinase C (PKC) pathways are the main pathways of insulin to the regulation of AQP9. Activation of the PKC pathway downregulates AQP9 mRNA and protein. Yamamoto et al. also found that PKA catalyst (db-cAMP) and PKA inhibitor (cycloheximide) can increase and decrease AQP9 expression, respectively, indicating that PKA pathway can up-regulate AQP9 expression.
Regulation of AQP9 by Hypoxia
Potomar et al. used RT-PCR to detect changes in the expression level of AQP9 gene during hypoxia and reoxygenation. It was found that AQP9 was mainly expressed on the astrocyte membrane; AQP9 mRNA showed a decrease in the first expression of hypoxia to reoxygenation and then increased gradually. The expression level of AQP9 mRNA was the same as that of the control group at 6 h after reoxygenation, and it was more than 2 times higher than the normal level after 9 h, indicating that the expression of AQP9 gene on the plasma membrane of astrocytes can be regulated by hypoxia.
Regulation of AQP9 by Osmotic Pressure
The study found that the AQP9 promoter region contains hyperosmotic response elements. Juutiuusitalo et al. studied the expression and regulation of AQP9 mRNA and protein in rat brain tissue under hypertonic conditions by applying hypertonic mannitol to cultured mouse astrocytes and injecting mannitol into the abdominal cavity of mice. The results showed that AQP9 gene and protein on astrocyte membrane were down-regulated by the p38MAPK inhibitor, while extracellular signal-regulated kinase (ERK) inhibitor and c-Jun N-terminal kinase (JNK) inhibitor had no effect on AQP9 expression. It is speculated that p38MAPK may be the major signal transduction pathway of AQP9 under hypertonic conditions.
AQP9 and Brain Disease
The study found that AQP9 expression is also present in special types of catecholamines such as adrenergic, noradrenergic, and dopaminergic neurons. It is speculated that the expression of AQP9 in such special neurons may be related to energy metabolism. Karlsson et al. used peroxidase immunofluorescence labeling to study the distribution of AQP9 in brain tissue of rats with cerebral ischemia-reperfusion. The results showed that the AQP9 immunolabeling of astrocytes around the ventricles was significantly increased. The periventricular organs include the lower organs of the humerus and the hypothalamus. They lack the blood-brain barrier and play an important role in the reflux of cerebrospinal fluid and the regulation of physiological functions of vasoactive substances. The distribution of AQP9 at the above sites suggests that AQP9 may be involved in regulating cerebrospinal fluid circulation, maintaining brain metabolic balance, maintaining normal function of brain cells and stabilizing the internal environment.
Intracranial hemorrhage (ICH) is a common subtype of stroke with high morbidity and mortality. AQP9 plays a key role in brain edema after ischemic stroke and traumatic brain injury and participates in the regulation of angiogenesis. Ji et al. have suggested that the AQP9 in the brain may play a compensatory role in the ICH response, promoting cerebral angiogenesis, and preventing subsequent neuronal death, thus AQP9 can prevent the deterioration of the ICH neurologic results. Wei et al. have studied the ischemic brain of rats with permanent middle cerebral artery occlusion (PMCAO) to elucidate the expression pattern of AQP9 and p38 mitogen activated protein kinase (MAPK) after ischemia. The results indicate that the dynamic changes of AQP9 expression mediated by p38MAPK signal transduction pathway may contribute to the development of cerebral edema after cerebral ischemia.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.